Marketing-authorisation holder
Hugel, Inc.
2 medicines in 1 country, as authorisation holder and manufacturer.
Medicines
Every medicine in the registers under its name, current ones first.
2 medicines
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| Letybo100units · For Injection | Botulinum toxin | United States | Marketed | 2024 |
| LETYBO0.1ml(4units) · Powder, for solution | Botulinum toxin | United States | Marketed | 2024 |
Countries
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 2 | 2 | 0 | CompaniesAll medicines |
Also in the registers of Brazil
Top substances
The active substances in most of its medicines.
Names in the registers
How the registers spell it, normalised: legal forms, accents and capitals removed.
- hugel
- hugel inc
Sources and licences
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Anvisa, official medicine/API manufacturer factual export, HTTP source version Fri, 09 Oct 2026 08:21:54 GMT, acquired 2026-10-09; exact unmodified native identifiers and fields preserved.
Licence: Brazil federal factual open-data reuse; Decreto 8777/2016 consolidated article 4 and third-party exceptions
FDA Purple Book, September 2026 release; acquired 2026-10-10T15:29:54.330165+00:00; exact source fields retained with source-key projections.
Licence: FDA-created structured factual administrative metadata; public-domain policy with third-party exceptions
Report an error or request removalCorrections from the company itself are welcome.
At a glance
- Type
- Marketing-authorisation holder
- Medicines
- 2
- Countries
- 1
- Roles
- Authorisation holder and manufacturer